- Previous Close
18.15 - Open
18.10 - Bid 16.92 x 800
- Ask 28.51 x 800
- Day's Range
17.77 - 18.41 - 52 Week Range
16.56 - 34.73 - Volume
456,037 - Avg. Volume
546,634 - Market Cap (intraday)
4.986B - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
39.72 - EPS (TTM)
0.46 - Earnings Date Nov 5, 2024
- Forward Dividend & Yield 0.06 (0.32%)
- Ex-Dividend Date Jun 4, 2024
- 1y Target Est
26.14
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
www.stevanatogroup.com5,635
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STVN
View More
Performance Overview: STVN
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STVN
View MoreValuation Measures
Market Cap
4.99B
Enterprise Value
5.29B
Trailing P/E
40.06
Forward P/E
33.56
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.24
Price/Book (mrq)
3.56
Enterprise Value/Revenue
4.56
Enterprise Value/EBITDA
31.18
Financial Highlights
Profitability and Income Statement
Profit Margin
10.48%
Return on Assets (ttm)
4.97%
Return on Equity (ttm)
9.48%
Revenue (ttm)
1.09B
Net Income Avi to Common (ttm)
114.7M
Diluted EPS (ttm)
0.46
Balance Sheet and Cash Flow
Total Cash (mrq)
79.49M
Total Debt/Equity (mrq)
27.60%
Levered Free Cash Flow (ttm)
-248.84M
Research Analysis: STVN
View MoreCompany Insights: STVN
STVN does not have Company Insights
Research Reports: STVN
View MoreDropping Coverage of Stevanato
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato's Sturdy Growth Shows No Signs of Slowing as Q2 Exceeds Forecasts; Shares Fairly Valued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target